ME00810B - Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke - Google Patents

Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke

Info

Publication number
ME00810B
ME00810B MEP-2009-213A MEP21309A ME00810B ME 00810 B ME00810 B ME 00810B ME P21309 A MEP21309 A ME P21309A ME 00810 B ME00810 B ME 00810B
Authority
ME
Montenegro
Prior art keywords
leptospira
virus
vaccine
bovine
cattle
Prior art date
Application number
MEP-2009-213A
Other languages
English (en)
French (fr)
Inventor
Paul Joseph Dominowski
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ME00810B publication Critical patent/ME00810B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi na kombinacione vakcine i metode za lečenje ili prevenciju oboljenja ili poremećaja kod životinja koje su izazvane infekcijom virusom goveđe virusne dijareje (BVDV) Tip l i 2, goveđim Herpes virusom Tip-l   (BH V -l); goveđim respiratornim 5 sincicijalnim virusom (BRSV), parainfluenca virusom (Ph), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis i Leptospira pomona, administriranjem životinji efektivne količine kombinacione vakcine. Kombinaciona   vakcina može biti preparat potpuno ili delimično inaktivirane ili modifikovane žive ćelije.
MEP-2009-213A 2002-08-26 2003-08-14 Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke ME00810B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40596902P 2002-08-26 2002-08-26
PCT/IB2003/003633 WO2004017990A1 (en) 2002-08-26 2003-08-14 Vaccine for respiratory and reproductive system infections in cattle

Publications (1)

Publication Number Publication Date
ME00810B true ME00810B (me) 2012-03-20

Family

ID=31946951

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-213A ME00810B (me) 2002-08-26 2003-08-14 Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke

Country Status (32)

Country Link
US (4) US20040081666A1 (me)
EP (2) EP1743652B1 (me)
JP (4) JP2006501237A (me)
KR (2) KR20050062542A (me)
CN (1) CN1315534C (me)
AP (1) AP2005003238A0 (me)
AR (1) AR041047A1 (me)
AT (1) ATE533506T1 (me)
AU (2) AU2003263390B2 (me)
BR (1) BR0313806A (me)
CA (1) CA2496750C (me)
EA (1) EA011578B1 (me)
GT (1) GT200300180A (me)
HK (1) HK1078457A1 (me)
HR (2) HRP20050192B1 (me)
IS (1) IS7672A (me)
MA (1) MA27388A1 (me)
ME (1) ME00810B (me)
MX (1) MXPA05002255A (me)
NO (1) NO20050603L (me)
NZ (2) NZ565206A (me)
OA (1) OA12915A (me)
PA (1) PA8581101A1 (me)
PE (1) PE20040420A1 (me)
PL (1) PL216541B1 (me)
RS (1) RS20050177A (me)
TN (1) TNSN05059A1 (me)
TW (1) TWI272105B (me)
UA (1) UA94689C2 (me)
UY (1) UY27948A1 (me)
WO (1) WO2004017990A1 (me)
ZA (1) ZA200501171B (me)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
CA2496750C (en) * 2002-08-26 2014-10-21 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
US7563449B2 (en) * 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
US7361357B2 (en) * 2003-07-29 2008-04-22 Pfizer Inc. Safe mutant viral vaccines
WO2005058356A2 (en) 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
JP5393978B2 (ja) * 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
US7572455B2 (en) * 2004-05-19 2009-08-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine comprising an attenuated pestivirus
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
EP2377550B1 (en) 2006-09-11 2015-03-04 Zoetis P LLC Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
WO2008036747A2 (en) * 2006-09-21 2008-03-27 Amarillo Biosciences, Inc. Composition and method for immunomodulation
US7803527B2 (en) * 2007-10-31 2010-09-28 Novartis Ag Inactivated bovine herpes virus-1 and methods
DK2224951T3 (da) * 2007-12-21 2020-01-06 Zoetis Services Llc Varmebehandlede bakteriner og emulsionsvacciner, der er fremstillet af sådanne varmebehandlede bakteriner
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
BRPI0920800A2 (pt) 2008-10-03 2020-08-11 Novartis Ag vírus da herpes bovina-1, composição, método para produzir uma resposta imunológica em um hospedeiro, e, uso de vírus da herpes bovina-1.
US8846054B2 (en) * 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
CA2836805C (en) * 2011-06-10 2023-03-07 Novartis Ag Bovine vaccines and methods
RU2522780C2 (ru) * 2012-07-27 2014-07-20 Государственное научное учреждение Всероссийский научно-исследовательский институт ветеринарной санитарии, гигиены и экологии Российской академии сельскохозяйственных наук Способ получения вакцины против инфекционного ринотрахеита крупного рогатого скота
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140147475A1 (en) 2012-11-29 2014-05-29 Antonius Arnoldus Christiaan Jacobs Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
MX357432B (es) 2013-03-18 2018-07-09 Intervet Int Bv Vacuna para proteger a un rumiante contra la neumonia causada por mannheimia haemolytica.
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
BR112018069371A2 (pt) 2016-03-21 2019-01-22 South Dakota Board Of Regents construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno
BR112019006900A2 (pt) 2016-10-05 2019-07-02 Zoetis Services Llc métodos de liofilização que proporcionam protozoários desidratados estáveis para o uso como potentes vacinas vivas
RU2643335C1 (ru) * 2016-11-14 2018-01-31 Федеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургская государственная академия ветеринарной медицины (ФГБОУ ВПО СПбГ АВМ) Инактивированная бивалентная гидроокись алюминиевая вакцина против кампилобактериоза собак
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN110317749B (zh) * 2019-06-19 2021-01-22 山东省农业科学院奶牛研究中心 一株牛支原体强毒株及其应用
RU2764220C1 (ru) * 2020-12-02 2022-01-14 Федеральное государственное бюджетное научное учреждение "Краснодарский научный центр по зоотехнии и ветеринарии" ФГБНУ КНЦЗВ Способ предупреждения риска заболевания парагриппом-3 у телят

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634587A (en) * 1969-11-06 1972-01-11 Ralston Purina Co Method of immunizing cattle against bovine respiratory disease syndrome
BE759425A (fr) * 1969-11-28 1971-05-25 Mebus Charles A Vaccins contre la diarrhee du veau, leur preparation et emploi
US5593873A (en) 1986-01-27 1997-01-14 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
DE3768232D1 (de) * 1986-12-19 1991-04-04 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
GB8818415D0 (en) * 1988-08-03 1988-09-07 Animal Health Inst Vaccine
US6291228B1 (en) * 1988-08-03 2001-09-18 Vericore Limited Vaccine
MX9301736A (es) 1992-03-30 1994-01-31 Smithkline Beecham Corp Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
EP0725831A1 (en) 1993-11-05 1996-08-14 PHARMACIA & UPJOHN COMPANY Viral vector with bovine viral diarrhea virus (bvdv) antigens
ZA953703B (en) * 1994-05-10 1996-01-10 American Home Prod Modified live BRSV vaccine
US5709865A (en) 1994-11-10 1998-01-20 Biostar Inc. Immunogenic composition against Bovine Viral Diarrhea Virus II glycoprotein 53 (BVDV-II gp53)
US6001613A (en) 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
US6060457A (en) 1996-06-20 2000-05-09 Universite De Montreal DNA plasmid vaccine for immunization of animals against BVDV
BR9803232A (pt) * 1997-08-26 2000-01-11 Pfizer Prod Inc Vaicna de neospora.
JP4426091B2 (ja) * 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
EP0924295A3 (en) * 1997-12-04 2001-05-16 Pfizer Products Inc. DNA encoding neospora dihydrofolate reductase-thymidylate synthase
CA2330086A1 (en) 1998-04-24 1999-11-04 Washington University Chimeras of hepatitis c virus and bovine viral diarrhea virus
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
CA2496750C (en) * 2002-08-26 2014-10-21 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
ES2365832T3 (es) 2007-03-05 2011-10-11 Cadila Healthcare Limited Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.

Also Published As

Publication number Publication date
JP2006501237A (ja) 2006-01-12
TNSN05059A1 (fr) 2007-05-14
PL216541B1 (pl) 2014-04-30
US20130129779A1 (en) 2013-05-23
AP2005003238A0 (en) 2005-03-31
HRP20090271A2 (en) 2009-11-30
NO20050603L (no) 2005-03-17
KR20060116037A (ko) 2006-11-13
HK1078457A1 (en) 2006-03-17
UA94689C2 (ru) 2011-06-10
CN1315534C (zh) 2007-05-16
ZA200501171B (en) 2006-12-27
EP1536830A1 (en) 2005-06-08
AU2003263390A1 (en) 2004-03-11
AU2008258154A1 (en) 2009-01-08
JP2009215309A (ja) 2009-09-24
US20070298053A1 (en) 2007-12-27
BR0313806A (pt) 2005-07-05
NZ565206A (en) 2008-12-24
AU2003263390B2 (en) 2008-12-18
IS7672A (is) 2005-01-27
EP1743652A1 (en) 2007-01-17
US20100266629A1 (en) 2010-10-21
EP1743652B1 (en) 2011-11-16
PA8581101A1 (es) 2005-11-25
HRP20050192B1 (hr) 2014-02-14
EA200500275A1 (ru) 2005-08-25
WO2004017990A1 (en) 2004-03-04
JP2012092126A (ja) 2012-05-17
GT200300180A (es) 2004-05-18
PE20040420A1 (es) 2004-07-24
AR041047A1 (es) 2005-04-27
EA011578B1 (ru) 2009-04-28
TW200404565A (en) 2004-04-01
KR20050062542A (ko) 2005-06-23
HRP20050192A2 (en) 2005-06-30
AU2008258154B2 (en) 2011-07-21
ATE533506T1 (de) 2011-12-15
JP2015172069A (ja) 2015-10-01
US9662384B2 (en) 2017-05-30
OA12915A (en) 2006-10-13
UY27948A1 (es) 2004-03-31
TWI272105B (en) 2007-02-01
MXPA05002255A (es) 2005-06-08
CA2496750C (en) 2014-10-21
RS20050177A (en) 2007-06-04
CN1678346A (zh) 2005-10-05
MA27388A1 (fr) 2005-06-01
JP5785073B2 (ja) 2015-09-24
CA2496750A1 (en) 2004-03-04
US20040081666A1 (en) 2004-04-29
PL375548A1 (en) 2005-11-28
NZ538394A (en) 2008-06-30

Similar Documents

Publication Publication Date Title
ME00810B (me) Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke
MXPA05011278A (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno.
Newcomer et al. Vaccination of cattle against bovine viral diarrhea virus
BG108496A (en) Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
Thiry et al. Reactivation of infectious bovine rhinotracheitis virus by transport
WO2003004051A3 (en) Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
WO2003003941A3 (en) One dose vaccination with mycoplasma hyopneumoniae
UA40571C2 (uk) Мутант коров'ячого вірусу герпесу типу 1 (bhv-1), композиція вакцини для вакцинації тварин для захисту їх від bhv-1, композиція вакцини для вакцинації тварин для захисту їх від патогена
RU2006133328A (ru) Способ вакцинации против инфекции семенников bvdv
DOP2003000699A (es) Vacunas para enfermedades reproductoras del ganado
WO2008106393A3 (en) Immunogenic compositions and methods for treating and preventing animal infections
JP5865839B2 (ja) 粘膜アジュバント組成物
CO5690616A2 (es) Vacunas para enfermedades reproductoras del ganado
Arricau-Bouvery et al. Only phase IQ fever vaccine protects pregnant goats against challenge with Coxiella burnetii
Lobetti Viral diseases of the dog.
Stokka Population dynamics and herd immunity
Vakhnij et al. Simulation of mass transfer in heterogeneous systems at multiple pulsed exposure to particle beams; Modelirovanie massoperenosa v geterogennykh sistemakh pri mnogokratnykh impul'snykh vozdejstviyakh puchkami chastits
Bagley Infectious Cattle Diseases and Vaccines
DE60033397D1 (de) Methode zur steigerung der produktionsleistung in tieren
Wagner Vaccination Practices in Cattle
Biuk-Rudan et al. Specific and non-specific protection of pigs exposed to contact infection with Aujeszky's disease virus (ADV)
Donescu et al. Epidemiology and control of Classical Swine Fever in Romania.
Sharon Effects of on-arrival, delayed vaccination and supplemental lysine on performance, antibody titer, temperature and metabolic profiles in response to modified-live viral respiratory vaccination
Makoschey et al. Combined application of an inactivated IBR marker vaccine and an inactivated BVD vaccine.